17289-53-1 Usage
Uses
Used in Pharmaceutical Synthesis:
N-(2,4-dimethylphenyl)-N2,N2-diethylglycinamide is used as an intermediate in the synthesis of various pharmaceuticals for its potential therapeutic applications.
Used in Cancer Treatment:
In the field of oncology, N-(2,4-dimethylphenyl)-N2,N2-diethylglycinamide is used as an inhibitor for the treatment of cancer. Its potential lies in targeting and managing the progression of the disease.
Used in Antibacterial Applications:
N-(2,4-dimethylphenyl)-N2,N2-diethylglycinamide is utilized as an antibacterial agent, effective against certain strains of bacteria, contributing to the development of new antimicrobial drugs.
Used in Antiviral Research:
Due to its potential antiviral properties, N-(2,4-dimethylphenyl)-N2,N2-diethylglycinamide is used in research for the development of antiviral medications, particularly for further investigation into its efficacy against viral infections.
Used in Drug Development:
In the pharmaceutical industry, N-(2,4-dimethylphenyl)-N2,N2-diethylglycinamide is a compound of interest for drug development, given its multifaceted potential in treating various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 17289-53-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,2,8 and 9 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 17289-53:
(7*1)+(6*7)+(5*2)+(4*8)+(3*9)+(2*5)+(1*3)=131
131 % 10 = 1
So 17289-53-1 is a valid CAS Registry Number.
17289-53-1Relevant academic research and scientific papers
Synthesis and antispasmodic activity of lidocaine derivatives endowed with reduced local anesthetic action
Costa, Jorge C.S.,Neves, Josiane S.,de Souza, Marcus V.N.,Siqueira, Rodrigo A.,Romeiro, Nelilma C.,Boechat, Nubia,Silva, Patricia M.R.e,Martins, Marco A.
, p. 1162 - 1166 (2008/09/20)
The present structure-activity relationship (SAR) study focused on chemical modifications of the structure of the local anesthetic lidocaine, and indicated analogues having reduced anesthetic potency, but with superior potency relative to the prototype in preventing anaphylactic or histamine-evoked ileum contraction. From the SAR analysis, 2-(diethylamino)-N-(trifluoromethyl-phenyl) and 2-(diethylamino)-N-(dimethyl-phenyl) acetamides were selected as the most promising compounds. New insights into the applicability of non-anesthetic lidocaine derivatives as templates in drug discovery for allergic syndromes are provided.
